&nbsp;

Jul 2023

Drug

pemetrexed

Other Name(s): Alimta®

Quick Link(s):

Apr 2023

Drug

SUNItinib

Other Name(s): Sutent®

Quick Link(s):

Sep 2023

Drug

pomalidomide

Other Name(s): Pomalyst®

Quick Link(s):

Aug 2023

Drug

ponatinib

Other Name(s): Iclusig®

Quick Link(s):

Aug 2023

Regimen

PCV

Cancer Type:

Central Nervous System

Intent: Adjuvant, Curative, Palliative

Funding:

ODB - General Benefit

procarbazine

ODB - General Benefit

lomustine

Drugs Used:

Quick Link(s):

Regimen Monograph

Jan 2023

Regimen

SORA

Cancer Type:

Gastrointestinal,

Hepatobiliary / Liver / Bile Duct

Intent: Palliative

Funding:

Exceptional Access Program

SORAfenib - Advanced hepatocellular carcinoma, with specific criteria

Drugs Used:

SORAfenib

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

PNTM

Cancer Type:

Gastrointestinal,

Colorectal,

Small bowel and appendix

Intent: Palliative

Funding:

New Drug Funding Program

Panitumumab - Metastatic Colorectal Small Bowel or Appendiceal Cancer

Drugs Used:

PANitumumab

Quick Link(s):

Regimen Monograph

Aug 2023

Regimen

PACL(W)+RAMU

Cancer Type:

Gastrointestinal,

Esophagus,

Gastric / Stomach

Intent: Palliative

Funding:

New Drug Funding Program

Ramucirumab - Advanced or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

Drugs Used:

ramucirumab,

PACLitaxel

Quick Link(s):

Regimen Monograph

Mar 2023

Regimen

PNAT

Cancer Type:

Hematologic,

Leukemia - Chronic Myeloid (CML)

Intent: Palliative

Funding:

Exceptional Access Program

ponatinib - For the treatment of Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia, according to specific clinical criteria

Drugs Used:

ponatinib